Breathe Well Live Well
|
Positive Phase II Asthma Clinical Trial Data
SYS-CON Media (press release) This pioneering trial investigated the potential for SNG001 (inhaled interferon beta) to protect asthmatics from respiratory virus infections (principally the common cold) that can spread to the lung, which are a major cause of worsening asthma … |
View full post on asthma – Google News
|
Targacept Reports Revised Top-Line Results From Phase 2 Study Of TC-6987
NASDAQ (RTTNews.com) – Targacept Inc. (TRGT) announced revised top-line results from its exploratory Phase 2 clinical study of TC-6987 in asthma. After identifying an error in the application of the agreed statistical analysis plan, a reanalysis of the data … Targacept Announces Revised Top-Line Results from Exploratory Phase 2 Study of … Targacept Announces Revised Top-Line Results from Exploratory Phase 2 Study |
View full post on asthma – Google News
|
Biota Reports Positive Phase IIb Data For Asthmatic Patients With HRV Infection
NASDAQ The Phase II multicenter, randomized, double-blind, placebo controlled study in asthmatic adults with symptomatic, naturally acquired human rhinovirus infection was conducted over two consecutive seasons in 48 centers in the US Subjects received either … Biota Announces Positive Phase IIb Data for Asthmatic Patients With Human … |
View full post on asthma – Google News
|
Biota Announces Positive Phase IIb Data for Asthmatic Patients With Human …
MarketWatch (press release) "While the clinical link between HRV infection and loss of asthma control is now widely accepted, Biota is the first company to evaluate the use of an antiviral to treat the infection in asthmatics. This has the potential to be of considerable benefit … |
View full post on asthma – Google News
|
Targacept Reports Top-Line Results From 2 Exploratory Phase 2 Studies Of TC-6987
RTT News (RTTNews) – Targacept Inc. (TRGT: News ) announced top-line results from two separate exploratory Phase 2 studies of its product candidate TC-6987 conducted in the US, one in asthma and one in type 2 diabetes. In the asthma study, oral TC-6987 met … Targacept Announces Top-Line Results from Two Exploratory Phase 2 Studies of … |
View full post on asthma – Google News
|
MediciNova completes enrollment in Phase II asthma trial
Pharmaceutical Business Review MediciNova has completed enrollment in its Phase II trial (MN-221-CL-007) evaluating the safety and efficacy of MN-221 for treatment of acute exacerbations of asthma. The randomized, double-blind trial enrolled a total of 176 asthma patients in the … MediciNova Completes Enrollment in Phase 2 MN-221 Trial Treating Patients … |
View full post on asthma – Google News
|
MediciNova Completes Enrollment in Phase 2 MN-221 Trial Treating Patients …
MarketWatch (press release) Patients suffering from acute exacerbations of asthma in the emergency room who were not promptly responding to standard pharmacotherapy were enrolled in the study. MediciNova is currently in the process of auditing and organizing the data and … |
View full post on asthma – Google News
|
Cytos to Secure up to CHF 37M to Advance Phase II Asthma Immunotherapy
Genetic Engineering News The funds will enable Cytos to conduct a global multicenter Phase IIb trial with its lead product CYT003-QbG10 in patients suffering from allergic asthma as well as to advance the rest of its pipeline. This transaction completes the financial … Cytos revives lead program in $40M financing deal with Amgen, venBio |
View full post on asthma – Google News
|
Baxter Presents Phase III HyQ Efficacy and Tolerability Data at American …
MarketWatch (press release) 5, during the American College of Allergy, Asthma and Immunology annual meeting in Boston. "In addition to a reduced rate of serious bacterial infections, the phase III study data suggest potentially useful attributes of HyQ, such as the possibility … |
View full post on asthma – Google News
|
Merck Announces Presentation of Phase III Investigational Studies Evaluating …
MarketWatch (press release) DULERA is indicated in the United States for the treatment of asthma in patients 12 years and older.(1) It is not indicated for the relief of acute bronchospasm or for the treatment of COPD. A supplemental new drug application (sNDA) for DULERA for the … |
View full post on asthma – Google News